165 related articles for article (PubMed ID: 6765415)
1. Species differences in susceptibilities of Proteeae spp. to six cephalosporins and three aminoglycosides.
Penner JL; Preston MA; Hennessy JN; Barton LJ; Goodbody MM
Antimicrob Agents Chemother; 1982 Aug; 22(2):218-21. PubMed ID: 6765415
[TBL] [Abstract][Full Text] [Related]
2. Differences among Providencia species in their in vitro susceptibilities to five antibiotics.
Penner JL; Preston MA
Antimicrob Agents Chemother; 1980 Dec; 18(6):868-71. PubMed ID: 7235674
[TBL] [Abstract][Full Text] [Related]
3. [Antimicrobial susceptibilities of clinical isolates of Morganella-proteus-providencia group of bacteria].
Igari J; Shitara M; Shitara M; Yoshimoto K; Hayashi Y
Jpn J Antibiot; 1991 Feb; 44(2):140-9. PubMed ID: 2041155
[TBL] [Abstract][Full Text] [Related]
4. Synergy between cephalosporin and aminoglycoside antibiotics against Providencia and Proteus.
Hyams PJ; Simberkoff MS; Rahal JJ
Antimicrob Agents Chemother; 1974 Jun; 5(6):571-7. PubMed ID: 15825407
[TBL] [Abstract][Full Text] [Related]
5. Speciation, serotyping, antimicrobial sensitivity and plasmid content of Proteeae from the environment of calf-rearing units in South West England.
Hawkey PM; Penner JL; Linton AH; Hawkey CA; Crisp LJ; Hinton M
J Hyg (Lond); 1986 Dec; 97(3):405-17. PubMed ID: 3540110
[TBL] [Abstract][Full Text] [Related]
6. [Enzymatic resistance to beta lactam antibiotics within the genus Proteus and evaluation of Proteus mirabilis phenotypes and genotypes for resistance to third- and fourth-generation cephalosporins].
Rodríguez C; Radice M; Perazzi B; Castro S; Juárez J; Santini P; Vay C; Famiglietti A; Gutkind G
Enferm Infecc Microbiol Clin; 2005 Mar; 23(3):122-6. PubMed ID: 15757582
[TBL] [Abstract][Full Text] [Related]
7. [Sensitivity to beta-lactam and aminoglycoside antibiotics of clinical Proteus strains as dependent upon on their species classification and the source of their isolation].
Shvidenko IG
Antibiot Med Biotekhnol; 1987 Nov; 32(11):850-5. PubMed ID: 3326520
[TBL] [Abstract][Full Text] [Related]
8. Comparative activities of the oxa-beta-lactam LY127935, cefotaxime, cefoperazone, cefamandole, and ticarcillin against multiply resistant gram-negative bacilli.
Hall WH; Opfer BJ; Gerding DN
Antimicrob Agents Chemother; 1980 Feb; 17(2):273-9. PubMed ID: 6247970
[TBL] [Abstract][Full Text] [Related]
9. The sensitivity of gentamicin-resistant gram-negative bacilli to cefotaxime, other cephalosporins and aminoglycosides.
Stephens M; Potten M; Bint AJ
Infection; 1979; 7(3):109-12. PubMed ID: 478651
[TBL] [Abstract][Full Text] [Related]
10. [Antimicrobial susceptibility patterns of the Proteeae in Japan, 1989].
Igari J; Hayashi Y; Shitara S; Shitara M; Yoshimoto K; Ohmizu Y; Umetsu M; Sasaki J; Kawana R; Yoshida T
Jpn J Antibiot; 1993 Apr; 46(4):285-94. PubMed ID: 8515560
[TBL] [Abstract][Full Text] [Related]
11. Comparative activity of tobramycin and gentamicin against Pseudomonas, Proteus and Providencia species.
Ducan IB; Penner JL
Can Med Assoc J; 1975 Jul; 113(1):29-31. PubMed ID: 807310
[TBL] [Abstract][Full Text] [Related]
12. Comparative susceptibilities of clinical isolates of Serratia marcescens to newer cephalosporins, alone and in combination with various aminoglycosides.
Markowitz SM; Sibilla DJ
Antimicrob Agents Chemother; 1980 Nov; 18(5):651-5. PubMed ID: 7004344
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of LY127935, a new 1-oxa cephalosporin, against aerobic gram-negative bacilli.
Delgado DG; Brau CJ; Cobbs CG; Dismukes WE
Antimicrob Agents Chemother; 1979 Dec; 16(6):864-8. PubMed ID: 533267
[TBL] [Abstract][Full Text] [Related]
14. Natural antibiotic susceptibility of Providencia stuartii, P. rettgeri, P. alcalifaciens and P. rustigianii strains.
Stock I; Wiedemann B
J Med Microbiol; 1998 Jul; 47(7):629-42. PubMed ID: 9839568
[TBL] [Abstract][Full Text] [Related]
15. Predictive accuracy of disk diffusion test for Proteus vulgaris and Providencia species against five newer orally administered cephalosporins, cefdinir, cefetamet, cefprozil, cefuroxime, and loracarbef.
Biedenbach DJ; Jones RN
J Clin Microbiol; 1994 Feb; 32(2):559-62. PubMed ID: 8150976
[TBL] [Abstract][Full Text] [Related]
16. Comparison of effectiveness of aminoglycosides and cephalosporins in gram-negative rods.
Vrbová E; Uxová M; Výmola F
Czech Med; 1986; 9(3):148-52. PubMed ID: 3095073
[TBL] [Abstract][Full Text] [Related]
17. Comparative in-vitro activity of quinolone carboxylic acids against Proteeae.
Hawkey PM; Hawkey CA
J Antimicrob Chemother; 1984 Nov; 14(5):485-9. PubMed ID: 6511707
[TBL] [Abstract][Full Text] [Related]
18. Aminoglycosides plus beta-lactams against gram-negative organisms. Evaluation of in vitro synergy and chemical interactions.
Giamarellou H
Am J Med; 1986 Jun; 80(6B):126-37. PubMed ID: 3088998
[TBL] [Abstract][Full Text] [Related]
19. [Patterns of resistance of Staph aureus and gram-negative bacteria to aminoglycosides and cephalosporins].
Ruczkowska J; Dolna I
Wiad Lek; 1989 May; 42(9):579-83. PubMed ID: 2629327
[TBL] [Abstract][Full Text] [Related]
20. Moxalactam (LY127935), a new semisynthetic 1-oxa-beta-lactam antibiotic with remarkable antimicrobial activity: in vitro comparison with cefamandole and tobramycin.
Jones RN; Fuchs PC; Sommers HM; Gavan TL; Barry AL; Gerlach EH
Antimicrob Agents Chemother; 1980 Apr; 17(4):750-6. PubMed ID: 6446880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
